Cidara Therapeutics Operating Income 2014-2022 | CDTX
Cidara Therapeutics operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Cidara Therapeutics Annual Operating Income
(Millions of US $) |
| 2021 |
$-42 |
| 2020 |
$-72 |
| 2019 |
$-42 |
| 2018 |
$-63 |
| 2017 |
$-56 |
| 2016 |
$-48 |
| 2015 |
$-32 |
| 2014 |
$-12 |
| 2013 |
$-1 |
Cidara Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-18 |
| 2021-12-31 |
$-17 |
| 2021-09-30 |
$-18 |
| 2021-06-30 |
$11 |
| 2021-03-31 |
$-18 |
| 2020-12-31 |
$-22 |
| 2020-09-30 |
$-18 |
| 2020-06-30 |
$-18 |
| 2020-03-31 |
$-15 |
| 2019-12-31 |
$-14 |
| 2019-09-30 |
$3 |
| 2019-06-30 |
$-14 |
| 2019-03-31 |
$-16 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-15 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-17 |
| 2017-12-31 |
$-13 |
| 2017-09-30 |
$-12 |
| 2017-06-30 |
$-17 |
| 2017-03-31 |
$-13 |
| 2016-12-31 |
$-14 |
| 2016-09-30 |
$-12 |
| 2016-06-30 |
$-12 |
| 2016-03-31 |
$-10 |
| 2015-12-31 |
$-10 |
| 2015-09-30 |
$-9 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-5 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$-3 |
| 2014-03-31 |
$-1 |
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.032B |
$0.050B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
